we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
Company profile
Ticker
BCDA
Exchange
Website
CEO
Peter Altman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
SEC CIK
Corporate docs
Subsidiaries
BioCardia Lifesciences, Inc. ...
IRS number
232753988
BCDA stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
4 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
S-8
Registration of securities for employees
27 Mar 24
8-K
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Mar 24
8-K
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
12 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
Transcripts
BCDA
Earnings call transcript
2023 Q3
8 Nov 23
BCDA
Earnings call transcript
2023 Q2
9 Aug 23
BCDA
Earnings call transcript
2023 Q1
10 May 23
BCDA
Earnings call transcript
2022 Q4
29 Mar 23
BCDA
Earnings call transcript
2022 Q3
13 Nov 22
BCDA
Earnings call transcript
2022 Q2
11 Aug 22
BCDA
Earnings call transcript
2022 Q1
11 May 22
BCDA
Earnings call transcript
2021 Q4
29 Mar 22
Latest ownership filings
4
Peter Altman
19 Apr 24
SC 13D/A
Frost Gamma Investments Trust
5 Apr 24
4
Peter Altman
28 Mar 24
SC 13D/A
Frost Gamma Investments Trust
27 Feb 24
4
Peter Altman
15 Feb 24
SC 13G/A
SATTERFIELD THOMAS A JR
14 Feb 24
SC 13D/A
Frost Gamma Investments Trust
6 Feb 24
SC 13G/A
Francis Capital Management, LLC
2 Feb 24
4
PHILLIP MD ET AL FROST
22 Jan 24
4
Andrew Scott Blank
19 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm |
Cash burn (monthly) | 823.33 k | 402.67 k | 866.00 k | 1.05 mm | 804.00 k | 926.67 k |
Cash used (since last report) | 5.65 mm | 2.76 mm | 5.94 mm | 7.19 mm | 5.52 mm | 6.36 mm |
Cash remaining | -3.81 mm | -927.80 k | -4.11 mm | -5.36 mm | -3.68 mm | -4.52 mm |
Runway (months of cash) | -4.6 | -2.3 | -4.7 | -5.1 | -4.6 | -4.9 |
Institutional ownership, Q2 2023
23.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 7 |
Closed positions | 4 |
Increased positions | 9 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 3.34 bn |
Total shares | 6.33 mm |
Total puts | 123.00 k |
Total calls | 192.60 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Frost Gamma Investments Trust | 2.14 mm | $3.65 mm |
Stertzer Simon H | 1.21 mm | $2.08 mm |
Francis Capital Management | 927.50 k | $0.00 |
Vanguard | 650.76 k | $1.74 bn |
CM Management | 343.00 k | $916.00 k |
Daly Joseph Patrick | 301.00 k | $509.00 k |
Geode Capital Management | 145.16 k | $387.56 mm |
Lynwood Capital Management | 128.92 k | $344.23 mm |
Advisor | 80.60 k | $156.46 mm |
Family Management | 77.50 k | $206.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 0.3683 | 2,750 | 1.01 k | 558,697 |
28 Mar 24 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 0.39 | 500 | 195.00 | 555,947 |
13 Feb 24 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 0.4625 | 108,108 | 50.00 k | 555,447 |
13 Feb 24 | Altman Peter | Warrant (right to buy Common Stock | Buy | Acquire P | No | No | 0.4423 | 54,054 | 23.91 k | 121,538 |
19 Jan 24 | Phillip MD Frost Et Al | Common Stock | Sell | Dispose S | Yes | No | 0.43 | 129,802 | 55.81 k | 1,896,025 |
18 Oct 23 | Bill Facteau | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4029 | 12,434 | 5.01 k | 12,434 |
18 Oct 23 | Bill Facteau | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4029 | 31,085 | 12.52 k | 31,085 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
BioCardia: Q4 Earnings Insights
27 Mar 24
BioCardia Q4 EPS $(0.09) Beats $(0.11) Estimate, Sales $13.00K Miss $90.00K Estimate
27 Mar 24
BioCardia Ended 2023 With Cash And Cash Equivalents Of $1.1M
27 Mar 24
Earnings Scheduled For March 27, 2024
27 Mar 24
Press releases
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27 Mar 24
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 Mar 24
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
12 Mar 24
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
4 Mar 24
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
8 Feb 24